Market size of Bio-Tech Sector
The Indian agricultural sector is predicted to increase to US$ 24 billion by 2025. India can be among the top five exporters of agro-commodities by shifting its focus on cultivation and effectively handholding farmers
The biotechnology sector in India is witnessing a strong growth trajectory and has proved to be highly inventive
India is among the top 12 biotechnology destinations in the world and the third-largest in the Asia-Pacific region.
The Indian biotech industry holds 3% of the global market share.
The Indian bioeconomy grew from US$ 70.2 billion in 2020 to US$ 80.12 billion in 2021, growing at 14.13%.
A total of 1,128 biotech startups were launched in 2021.
The Indian biotechnology industry is likely to reach US$ 150 billion by 2025.
Opportunities in various segments
- All
- BIO-Services
- Bio-Industrials
- Bio-Pharma
- Bio-Agri
- Bio-IT
BIO-Services
India has potential for clinical trials due to alarge and low-cost market.
Clinical trials in India are regulated by the Central Drug Standard Control Organisation, which has reduced approval time to about 30-60 days
Bio-Industrials
Biofuels and bioenergy are considered alternative resources and are gaining popularity in India.
Rise in energy demand is leading to an increase in dependence on fossil fuel imports.
Bio-Pharma
The Indian biologics market is expected to register a CAGR of 22% from 2019 to 2025, to reach US$ 12 billion by 2025.
The Indian biologics market is expected to register a CAGR of 22% from 2019 to 2025.
Bio-Agri
India’s Union budget 2021-22 stated the government’s plan to enhance farm productivity and focus on food security.
This increased the importance of bioagriculture, which will enhance efficient food production.
Bio-IT
Biotechnology has immense growth potential in the Bio-IT segment, given the rising need for technology.
India’s IT industry is witnessing substantial growth and has the requisite IT infrastructure to cater to the needs of the global Bio-IT industry.
India is likely to witness > 100million diabetics by 2030.With the rising number of patients,~50% are undiagnosed,providing domestic market opportunity to the country.
Why We Choose
